The Patent Finder

Musc Foundation for Research Development

105 patents currently held · Updated Nov 15, 2026
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 7 name spellings.

15
Ending by 2030
Jun 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 9 to 14, 2027 · next Jan 9
  • 4 fees due Feb 6 to 27, 2027 · next Feb 6
  • 4 fees due Apr 1 to 22, 2027 · next Apr 1
  • 3 fees due May 7 to 21, 2027 · next May 7
  • 2 fees due Jun 5 to 10, 2027 · next Jun 5
  • 1 fee due Jul 30, 2027
    The maintenance fee for CD38-NAD+ Regulated Metabolic Axis in Anti-Tumor Immunotherapy (US 11,883,430) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
  • 2 fees due Aug 16 to 27, 2027 · next Aug 16
  • 3 fees due Sep 5 to 26, 2027 · next Sep 5
  • 1 fee due Oct 23, 2027
    The maintenance fee for Activated CD26-HIGH Immune Cells and CD26-Negative Immune Cells and Uses Thereof (US 11,963,980) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for T Regulatory (Treg) Cell Transplantation in Osteogenesis Imperfecta (OI) (US 11,975,024) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 17, 2026
  • 9 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,759,304Targeting Complement Factor H for Treatment of Diseases
In force
 · High confidence
In forceHigh confidence
US 9,212,212Targeting Complement Factor H for Treatment of Diseases
In force
 · Medium confidence
In forceMedium confidence
US 8,735,365Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
In force
 · Low confidence
In forceLow confidence
US 8,623,617Detecting PAX2 for the Diagnosis of Breast Cancer
In force (reinstated)
 · Low confidence
In force (reinstated)Low confidence
US 8,722,367Detecting PAX2 for the Diagnosis of Breast Cancer
In force
 · Low confidence
In forceLow confidence
US 8,241,905Self-Assembling Cell Aggregates and Methods of Making Engineered Tissue Using the Same
In force
 · High confidence
In forceHigh confidence
US 8,088,603Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions
In force
 · High confidence
In forceHigh confidence
US 8,569,225Targeting Complement Factor H for Treatment of Diseases
In force
 · Medium confidence
In forceMedium confidence
US 8,506,499Predicting Atrial Fibrillation Recurrence by Protease and Protease Inhibitor Profiling
In force
 · High confidence
In forceHigh confidence
US 8,489,186Devices and Methods for Treatment of Myocardial Conditions
In force
 · High confidence
In forceHigh confidence
10 of 105 patents shown.
Pro members see all 105.
Pro members: see all 105 patents
Also on record, not counted in the 105: 9 patents in force now held by others · 78 lapsed for an unpaid fee · 38 ended at full term · 1 past the fee grace period · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

25 pending · 65 abandoned · 17 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited